What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “4D-110 drug product developed for gene therapy which comprises an AAV capsid variant (4D-R100) carrying a transgene encoding a codon-optimized human CHM gene.”In the company’s words, NCT04483440 on ClinicalTrials.gov
- Tested for
- Choroideremia
- Main trialPhase 1
- “This study will evaluate safety, tolerability, and preliminary efficacy of a single intravitreal (IVT) injection of a recombinant adeno-associated virus (AAV) gene therapy, 4D-110, in male patients with genetically-confirmed Choroideremia (CHM).”In the company’s words, NCT04483440 on ClinicalTrials.gov
Coming up1
- 26 May 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 26 May 2027 | Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026